These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24691172)

  • 41. Invasive aspergillosis mimicking stage IIIA non-small-cell lung cancer on FDG positron emission tomography.
    Wilkinson MD; Fulham MJ; McCaughan BC; Constable CJ
    Clin Nucl Med; 2003 Mar; 28(3):234-5. PubMed ID: 12592137
    [No Abstract]   [Full Text] [Related]  

  • 42. Spectrum of 18F-FDG PET/CT findings in oncology-related recurrent laryngeal nerve palsy.
    Komissarova M; Wong KK; Piert M; Mukherji SK; Fig LM
    AJR Am J Roentgenol; 2009 Jan; 192(1):288-94. PubMed ID: 19098212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
    Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. False-positive findings on [18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer.
    Ohtsuka T; Nomori H; Watanabe K; Naruke T; Orikasa H; Yamazaki K; Suemasu K; Uno K
    Jpn J Clin Oncol; 2005 May; 35(5):271-3. PubMed ID: 15883125
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients.
    Takamochi K; Yoshida J; Murakami K; Niho S; Ishii G; Nishimura M; Nishiwaki Y; Suzuki K; Nagai K
    Lung Cancer; 2005 Feb; 47(2):235-42. PubMed ID: 15639722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic value of dual time-point 18 F-FDG PET/CT versus single time-point imaging for detection of mediastinal nodal metastasis in non-small cell lung cancer patients: a meta-analysis.
    Shen G; Hu S; Deng H; Jia Z
    Acta Radiol; 2015 Jun; 56(6):681-7. PubMed ID: 24917609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans.
    Eloubeidi MA; Cerfolio RJ; Chen VK; Desmond R; Syed S; Ojha B
    Ann Thorac Surg; 2005 Jan; 79(1):263-8. PubMed ID: 15620955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is a selective brain (18)F-FDG PET/CT study profitable in patients with small cell lung cancer?
    Palomar Muñoz A; García Vicente AM; Bellón Guardia ME; González García B; Talavera Rubio MP; Pilkington Woll JP; Núñez García A; Poblete García VM; Cordero García JM; Soriano Castrejón A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):124-9. PubMed ID: 21722995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma.
    Chu MM; Kositwattanarerk A; Lee DJ; Makkar JS; Genden EM; Kao J; Packer SH; Som PM; Kostakoglu L
    Radiographics; 2010 Sep; 30(5):1353-72. PubMed ID: 20833855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDG uptake in abdominal mesh implant on FDG PET/CT.
    Yilmaz M; Sevinc A; Aybasti N; Celen Z; Zincirkeser S
    Clin Nucl Med; 2008 May; 33(5):351-2. PubMed ID: 18431155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging.
    Chung JH; Cho KJ; Lee SS; Baek HJ; Park JH; Cheon GJ; Choi CW; Lim SM
    J Nucl Med; 2004 Jun; 45(6):999-1003. PubMed ID: 15181136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new method to assess pulmonary changes using
    Abravan A; Knudtsen IS; Eide HA; Løndalen AM; Helland Å; van Luijk P; Malinen E
    Acta Oncol; 2017 Nov; 56(11):1597-1603. PubMed ID: 28849707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer.
    Song JW; Oh YM; Shim TS; Kim WS; Ryu JS; Choi CM
    Lung Cancer; 2009 Sep; 65(3):333-8. PubMed ID: 19144446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.